DGX monthly performance report
Monthly DGX research: returns, drawdown, relative strength, seasonality, and key stats.
DGX monthly report
—
Key takeaways
- Quest Diagnostics (DGX) closed August 2026 at $235.84, up 1.21% for the month and +36.11% over the trailing 12 months.
- Year-to-date, DGX is +35.91%, outperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +21.16% versus its 200-day moving average ($194.66), a bullish technical signal.
- Over the past three years, DGX has outperformed the S&P 500 by +1.57%, with a relative strength index reading of 101.1.
- Win rate over the trailing 39 months stands at 64.1% — 25 positive months versus 14 negative months.
Quest Diagnostics ended August 2026 at $235.84, posting a monthly return of +1.21%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −1.83%.
The current quarter stands at +10.88% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +21.16% versus the 200-day moving average ($194.66).
Year-to-date, DGX is +35.91% against SPY +12.89%, a gap of +23.02%. The stock is currently −1.74% below its 52-week high, with maximum 3-year drawdown at −12.90%.
| Period | DGX | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.91% | −0.20% | +1.11% |
| 1 Week | −0.04% | +3.90% | −3.95% |
| 1 Month | +1.21% | +3.05% | −1.83% |
| 3 Months | +21.44% | +7.11% | +14.33% |
| 6 Months |